NASDAQ:BLPHBellerophon Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bellerophon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.97 -0.05 (-0.38 %) (As of 07/13/2020 04:00 PM ET) Add Compare Share Today's Range$12.86Now: $12.97▼$13.2650-Day Range$12.18MA: $13.27▼$14.8752-Week Range$3.19Now: $12.97▼$26.00Volume106,000 shsAverage Volume575,290 shsMarket Capitalization$123.19 millionP/E RatioN/ADividend YieldN/ABeta-0.78 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingBellerophon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.67, Bellerophon Therapeutics has a potential upside of 144.2% from its current price of $12.97.Amount of Analyst CoverageBellerophon Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesBellerophon Therapeutics has received 306 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBellerophon Therapeutics has received 206 “underperform” votes. (Add your “underperform” vote.)Community SentimentBellerophon Therapeutics has received 59.77% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote “Outperform” if you believe BLPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BLPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBellerophon Therapeutics does not currently pay a dividend.Dividend GrowthBellerophon Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bellerophon Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders38.50% of the stock of Bellerophon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.15% of the stock of Bellerophon Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bellerophon Therapeutics are expected to grow in the coming year, from ($1.79) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bellerophon Therapeutics is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bellerophon Therapeutics is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBellerophon Therapeutics has a P/B Ratio of 16.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLPH Previous Symbol CUSIPN/A CIK1600132 Webwww.bellerophon.com Phone908-574-4770Debt Debt-to-Equity Ratio0.69 Current Ratio1.34 Quick Ratio1.34Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book16.63Profitability EPS (Most Recent Fiscal Year)($2.95) Net Income$-13,270,000.00 Net MarginsN/A Return on Equity-269.64% Return on Assets-106.98%Miscellaneous Employees17 Outstanding Shares9,498,000Market Cap$123.19 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:BLPH Rates by TradingView Receive BLPH News and Ratings via Email Sign-up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter. Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions How has Bellerophon Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BLPH stock has increased by 106.2% and is now trading at $12.97. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Bellerophon Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellerophon Therapeutics. When is Bellerophon Therapeutics' next earnings date? Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Bellerophon Therapeutics. How were Bellerophon Therapeutics' earnings last quarter? Bellerophon Therapeutics Inc (NASDAQ:BLPH) issued its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.02) by $0.13. View Bellerophon Therapeutics' earnings history. When did Bellerophon Therapeutics' stock split? How did Bellerophon Therapeutics' stock split work? Bellerophon Therapeutics shares reverse split before market open on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split. What price target have analysts set for BLPH? 3 Wall Street analysts have issued 1 year target prices for Bellerophon Therapeutics' shares. Their forecasts range from $30.00 to $35.00. On average, they anticipate Bellerophon Therapeutics' share price to reach $31.67 in the next twelve months. This suggests a possible upside of 144.2% from the stock's current price. View analysts' price targets for Bellerophon Therapeutics. Has Bellerophon Therapeutics been receiving favorable news coverage? News headlines about BLPH stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Bellerophon Therapeutics earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Bellerophon Therapeutics. Are investors shorting Bellerophon Therapeutics? Bellerophon Therapeutics saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 380,700 shares, an increase of 245.5% from the June 15th total of 110,200 shares. Based on an average daily volume of 451,600 shares, the days-to-cover ratio is presently 0.8 days. Currently, 7.1% of the shares of the stock are short sold. View Bellerophon Therapeutics' Current Options Chain. Who are some of Bellerophon Therapeutics' key competitors? Some companies that are related to Bellerophon Therapeutics include NextCure (NXTC), Urogen Pharma (URGN), Mirum Pharmaceuticals (MIRM), Emisphere Technologies (EMIS), AC Immune (ACIU), BioSpecifics Technologies (BSTC), Neoleukin Therapeutics (NLTX), Xenon Pharmaceuticals (XENE), Flexion Therapeutics (FLXN), Beyondspring (BYSI), Prothena (PRTA), Fulcrum Therapeutics (FULC), Osmotica Pharmaceuticals (OSMT), Satsuma Pharmaceuticals (STSA) and Protagonist Therapeutics (PTGX). View all competitors. What other stocks do shareholders of Bellerophon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Vaxart (VXRT), Novavax (NVAX), VBI Vaccines (VBIV), Opko Health (OPK), Verastem (VSTM), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Clovis Oncology (CLVS). Who are Bellerophon Therapeutics' key executives? Bellerophon Therapeutics' management team includes the following people: Fabian Tenenbaum, Chief Executive Officer & DirectorAssaf Korner, Chief Financial Officer & SecretaryAmy Edmonds, VP-Clinical Operations & AdministrationMartin Dekker, Vice President-Engineering & ManufacturingPeter Fernandes, Chief Regulatory & Safety Officer When did Bellerophon Therapeutics IPO? (BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers. What is Bellerophon Therapeutics' stock symbol? Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH." How do I buy shares of Bellerophon Therapeutics? Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Bellerophon Therapeutics' stock price today? One share of BLPH stock can currently be purchased for approximately $12.97. How big of a company is Bellerophon Therapeutics? Bellerophon Therapeutics has a market capitalization of $123.19 million. The biotechnology company earns $-13,270,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe. What is Bellerophon Therapeutics' official website? The official website for Bellerophon Therapeutics is www.bellerophon.com. How can I contact Bellerophon Therapeutics? Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
